2007 Fiscal Year Final Research Report Summary
Development of new cancer immunotherapy using activation of Toll like receptor against gastrointestinal cancer
| Project/Area Number |
18591479
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
MATSUDA Kenji Wakayama Medical University, School of Medicine, Second Department of Surgery, Instructor (30398458)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMUE Hiroki Wakayama Medical University, School of Medicine, Second Department of Surgery, Professor (20191190)
IWAHASHI Makoto Wakayama Medical University, School of Medicine, Second Department of Surgery, Assistant professor (70244738)
TANI Masaji Wakayama Medical University, School of Medicine, Second Department of Surgery, Assistant professor (60236677)
HOTTA Tsukasa Wakayama Medical University, School of Medicine, Second Department of Surgery, Assistant professor (50244744)
NAKAMORI Mikihito Wakayama Medical University, School of Medicine, Second Department of Surgery, Assistant professor (10322372)
NAKAMURA Masaki Wakayama Medical University, School of Medicine, Second Department of Surgery, Instructor (80364090)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | CDG-ODN / peptide / immunotherapy |
|---|
| Research Abstract |
CpG oligodeoxynucleotides (CpG-ODNs) mimic bacterial DNA and induce immune response that comprise innate immunity and acquired Th-1 biased cellular immunity. Recently, 3 types of CpG-ODNs (CpG-A, CpG-B and CpG-C) have been identified based on distinct immunologic activities on human plasmacytoid dendritic cells (PDCs) and B cells. We investigated the activity of these three types of CpG-ODN to enhance the induction of peptide specific CTLs. First, human PBMCs of healthy volunteers were stimulated with each types of CpG-ODN for 48 hours. Samples of the culture media were analyzed for cytokine induction with ELISA method. CpG-A and CpG-C, but not CpG-B, were potent inducers of IFN-α. Second, Flu peptide-specific CTLs were generated from PBMCs cultured with Flu peptide and each types of CpG-ODN for 2 weeks to compare the lytic activity against A24-LCL cells pulsed with Flu peptide in a standard Cr lysis assay. Flu peptide-specific cytotoxicity was enhanced in the presence of each type of CpG-ODN and especially CpG-A and CpG-C showed higher lytic activity than CpG-B. This CpG ODN-induced enhancement of cytotoxicity was disappeared when PDCs were depleted from PBMCs. In conclusion, our results showed that CpG-A and CpG-C might be the superior vaccine adjuvant to CpG-B at least in vitro.
|
